Your Health, We Care
On March 19, 2024, the FDA accelerated the approval of ponatinib combined with first-line chemotherapy for newly diagnosed adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL).
Ponatinib, as a third-generation Bcr Abl kinase inhibitor, has shown significant efficacy in multiple clinical trials for chronic myeloid leukemia (CML) in resistant or intolerant chronic, accelerated, or acute phases, as well as for Ph+ALL patients.
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
